RxDoctor Payments Data

Francisco Cordova Perez, MD

Cardiovascular Disease · San Juan, PRNPI 1427082635

Payments from drug & device makers

$1,058in general payments, 2019–2025

Across 24 payments — averaging $44.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$325
  • United Therapeutics Corporation$190
  • PBG Puerto Rico LLC$129
  • Boehringer Ingelheim$116
  • Actelion Pharmaceuticals US, Inc.$100
  • E.r. Squibb & Sons, L.L.C.$75
  • plus $123 from 4 others

What the payments were for

  • Consulting fees$20019%
  • Food & beverage$85881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,058 in reported general payments places this provider in the 30th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$1,118
Medicare patients
11
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban49$38,756
FarxigaDapagliflozin Propanediol35$31,579
EliquisApixaban46$28,907
EntrestoSacubitril/Valsartan31$22,101
JardianceEmpagliflozin24$18,115
BrilintaTicagrelor15$6,840
SynthroidLevothyroxine Sodium38$2,870
Candesartan Cilexetil17$2,000
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$1,730
Metoprolol Succinate92$1,638
Atorvastatin Calcium144$1,461
Losartan Potassium113$1,158
Rosuvastatin Calcium65$1,099
Amiodarone Hcl17$1,011
Sildenafil Citrate12$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$50$38,75649 claims
AstraZenecaFarxiga, Brilinta$16$38,41950 claims
Boehringer IngelheimJardiance$116$18,11524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →